CardioDx postpones $75 million IPO

Comment

Shutterstock photo

CardioDx, which sells a diagnostic test for coronary artery disease, postponed its IPO on Thursday, citing poor market conditions. The Palo Alto, CA-based company was founded in 2003 and booked $7 million in sales for the 12 months ended 9/30/2013. CardioDx initially filed confidentially on 7/24/2013. BofA Merrill Lynch and Jefferies & Co. were set to be the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com